Lexicon Pharmaceuticals , Inc. ( LXRX ) Q4 2013 Earnings Conference Call February 28, 2014 11 ..... At this time, I would like to welcome everyone to the Lexicon Pharmaceuticals ’ Earnings Conference Call. (Operator Instructions
Lexicon Pharmaceuticals ( LXRX ): Q4 EPS of -$0.03. Revenue of $1.4M misses by $0.26M . Press Release Post your comment!
Morningstar rating change from 4-5 Stars. Does anyone buy or sell, based on M rating changes?
Lexicon Pharmaceuticals announced that longtime CEO and cofounder Arthur Sands plans to depart the firm, and that it will cut 45% of its workforce
background in cardiovascular disease and endocrinology, which is critical for the firm's LX4211 program. Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising
Lexicon Pharmaceuticals LXRX reported second-quarter results that put it on track to meet our forecast for the year, and we're maintaining our $3.50
Lexicon LXRX has released data from a Phase 2b study of LX4211, and we're maintaining our fair value estimate as we expect the firm to move
(Reuters) - Lexicon Pharmaceuticals Inc said its experimental diabetes drug, along with metformin, reduced average blood glucose levels compared with a placebo in a mid-stage trial.
Lexicon Pharmaceuticals LXRX reported first-quarter results that were in line with our expectations, and we're maintaining our fair value estimate as we
Lexicon's LXRX third-quarter results put the firm on track to meet our cash burn expectations for 2011, and we're maintaining our fair value